Drug Profile
Research programme: antibody-drug conjugates - Merck/Tel Aviv University
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Ramot at Tel Aviv University
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer